International Biotechnology (LON:IBT) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Key Points

• International Biotechnology's stock price recently crossed above its 200-day moving average at GBX 624.28, peaking at GBX 658 during trading.
• The company reported a net margin of 90.66% and a return on equity of 13.67%, with expected earnings per share of 0.94 this year.
• Insider Katherine Cornish-Bowden bought 2,000 shares at GBX 585, indicating confidence in the company's future performance.

International Biotechnology (LON:IBT - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 624.28 ($8.40) and traded as high as GBX 658 ($8.85). International Biotechnology shares last traded at GBX 656 ($8.82), with a volume of 426,698 shares changing hands.

International Biotechnology Price Performance

The business has a fifty day simple moving average of GBX 617.48 and a two-hundred day simple moving average of GBX 623.24. The company has a market capitalization of £232.77 million, a price-to-earnings ratio of 6.18 and a beta of 0.21.

International Biotechnology (LON:IBT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported GBX (5.60) (($0.08)) EPS for the quarter. International Biotechnology had a return on equity of 13.67% and a net margin of 90.66%. As a group, equities analysts predict that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year.

Insider Activity at International Biotechnology

In other International Biotechnology news, insider Katherine Cornish-Bowden bought 2,000 shares of International Biotechnology stock in a transaction dated Tuesday, May 13th. The shares were acquired at an average cost of GBX 585 ($7.87) per share, with a total value of £11,700 ($15,736.38). 4.18% of the stock is owned by insiders.

About International Biotechnology

The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.